Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Mark A. Goldsmith Ph.D. | CEO, President & Chairman | 1.12M | 2.85M | 1962 |
| Mr. Jack Anders | Chief Financial Officer | 665.28k | 1.02M | 1976 |
| Ms. Margaret A. Horn J.D. | Chief Operating Officer | 811.08k | 1.68M | 1963 |
| Dr. Stephen M. Kelsey FRC Path., FRCP, M.D. | President of Research & Development | 812.17k | -- | 1961 |
| Ms. Xiaolin Wang | Executive Vice President of Development | 633.74k | -- | 1971 |
| Dr. Martin D. Burke M.D., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | -- | -- | -- |
| Dr. Michael A. Fischbach Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | -- | -- | 1981 |
| Dr. Kevan M. Shokat Ph.D. | Academic Co-Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Mr. Walter Reiher Ph.D. | Chief Information Officer | -- | -- | -- |
| Ms. Jan Smith Ph.D. | Chief Scientific Officer | -- | -- | -- |
Revolution Medicines, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 490
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Corporate Governance
Upcoming Events
February 24, 2025 at 9:00 PM UTC - February 28, 2025 at 9:00 PM UTC
Revolution Medicines, Inc. Earnings Date
Recent Events
October 25, 2024 at 4:00 PM UTC
To Discuss PDAC Data From The RMC-6236 and RMC-9805 Monotherapy Studies Call